Benjamin Tan
Research Subjects
Benjamin Tan has a total of 143 co-authors. Here are the top co-authors by number of shared publications:
- Alan P. Venook
Helen Diller Family Comprehensive Cancer Center 1 San Francisco, California
65 shared publications - Eileen Mary O'Reilly
Weill Cornell Medicine
65 shared publications - Jeffrey A. Meyerhardt
Department of Medical Oncology, Dana-Farber Cancer Institute , Boston, MA
65 shared publications - Qian Shi
Alliance Statistics and Data Management Center, Mayo Clinic , Rochester, MN
65 shared publications - Tyler Zemla
Mayo Clinic, Rochester, MN
65 shared publications - Anthony F. Shields
Karmanos Cancer Institute, Wayne State University, Detroit, Michigan
64 shared publications
Latest Publications
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S5 from Plasma 25-Hydroxyvitamin D Levels and Survival in Stage III Colon Cancer: Findings from CALGB/SWOG 80702 (Alliance)
Table S5. Hazard ratio of cancer-specific mortality by plasma 25-hydroxyvitamin D levels in plasma biomarker companion study and by predicted vitamin D scores in diet and lifestyle companion study
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S5 from Plasma 25-Hydroxyvitamin D Levels and Survival in Stage III Colon Cancer: Findings from CALGB/SWOG 80702 (Alliance)
Table S5. Hazard ratio of cancer-specific mortality by plasma 25-hydroxyvitamin D levels in plasma biomarker companion study and by predicted vitamin D scores in diet and lifestyle companion study
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from Plasma 25-Hydroxyvitamin D Levels and Survival in Stage III Colon Cancer: Findings from CALGB/SWOG 80702 (Alliance)
Table S3. Sensitivity analysis of the association between plasma 25-hydroxyvitamin level and disease-free survival, overall survival, and time to recurrence, excluding patients who recurred or died within three months of blood collection
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from Plasma 25-Hydroxyvitamin D Levels and Survival in Stage III Colon Cancer: Findings from CALGB/SWOG 80702 (Alliance)
Table S3. Sensitivity analysis of the association between plasma 25-hydroxyvitamin level and disease-free survival, overall survival, and time to recurrence, excluding patients who recurred or died within three months of blood collection
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Plasma 25-Hydroxyvitamin D Levels and Survival in Stage III Colon Cancer: Findings from CALGB/SWOG 80702 (Alliance)
Table S1. Baseline characteristics of study participants in the complete clinical trial, plasma biomarker companion study, and diet and lifestyle companion study
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Plasma 25-Hydroxyvitamin D Levels and Survival in Stage III Colon Cancer: Findings from CALGB/SWOG 80702 (Alliance)
Table S1. Baseline characteristics of study participants in the complete clinical trial, plasma biomarker companion study, and diet and lifestyle companion study
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Table S1 from Defactinib, Pembrolizumab, and Gemcitabine in Patients with Advanced Treatment Refractory Pancreatic Cancer: A Phase I Dose Escalation and Expansion Study
Supplemental Table 1 Patient demographics
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S1 from Defactinib, Pembrolizumab, and Gemcitabine in Patients with Advanced Treatment Refractory Pancreatic Cancer: A Phase I Dose Escalation and Expansion Study
Supplemental Table 1 Patient demographics
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from Plasma 25-Hydroxyvitamin D Levels and Survival in Stage III Colon Cancer: Findings from CALGB/SWOG 80702 (Alliance)
Figure S2. Dose-response relationship and test of linearity for the hazard ratio (HR) of disease-free survival (A), overall survival (B), and time to recurrence (C) by continuous predicted vitamin D scores, with reference of plasma 25-hydroxyvitamin D set at 12 ng/ml
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from Plasma 25-Hydroxyvitamin D Levels and Survival in Stage III Colon Cancer: Findings from CALGB/SWOG 80702 (Alliance)
Figure S2. Dose-response relationship and test of linearity for the hazard ratio (HR) of disease-free survival (A), overall survival (B), and time to recurrence (C) by continuous predicted vitamin D scores, with reference of plasma 25-hydroxyvitamin D set at 12 ng/ml
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S4 from Plasma 25-Hydroxyvitamin D Levels and Survival in Stage III Colon Cancer: Findings from CALGB/SWOG 80702 (Alliance)
Table S4. Hazard ratio of disease-free survival, overall survival, time to recurrence by quartiles of predicted vitamin D score
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S4 from Plasma 25-Hydroxyvitamin D Levels and Survival in Stage III Colon Cancer: Findings from CALGB/SWOG 80702 (Alliance)
Table S4. Hazard ratio of disease-free survival, overall survival, time to recurrence by quartiles of predicted vitamin D score
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Table S2 from Defactinib, Pembrolizumab, and Gemcitabine in Patients with Advanced Treatment Refractory Pancreatic Cancer: A Phase I Dose Escalation and Expansion Study
Supplemental Table 2 Patient demographics
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S2 from Defactinib, Pembrolizumab, and Gemcitabine in Patients with Advanced Treatment Refractory Pancreatic Cancer: A Phase I Dose Escalation and Expansion Study
Supplemental Table 2 Patient demographics
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from Plasma 25-Hydroxyvitamin D Levels and Survival in Stage III Colon Cancer: Findings from CALGB/SWOG 80702 (Alliance)
Figure S1. Diagram for study cohort derivation
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from Plasma 25-Hydroxyvitamin D Levels and Survival in Stage III Colon Cancer: Findings from CALGB/SWOG 80702 (Alliance)
Figure S1. Diagram for study cohort derivation
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from Plasma 25-Hydroxyvitamin D Levels and Survival in Stage III Colon Cancer: Findings from CALGB/SWOG 80702 (Alliance)
Figure S3. Multivariable hazard ratio and 95% confidence intervals for disease-free survival (A), overall survival (B), and time to recurrence (C), comparing plasma 25-hydroxyvitamin D ≥12 versus <12 ng/ml, across strata of potential effect modifiers
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from Plasma 25-Hydroxyvitamin D Levels and Survival in Stage III Colon Cancer: Findings from CALGB/SWOG 80702 (Alliance)
Figure S3. Multivariable hazard ratio and 95% confidence intervals for disease-free survival (A), overall survival (B), and time to recurrence (C), comparing plasma 25-hydroxyvitamin D ≥12 versus <12 ng/ml, across strata of potential effect modifiers